By Ben LevisohnSunTrust Robinson Humphrey’s Edward Nash and team offer five biotech stocks for the next six months:
Cempra (CEMP) ($50 PT), our top pick based on near-term clinical and commercial success potential. We recently met with management and it was reiterated that the second Phase III study of solithromycin in CABP (SOLITAIRE-IV) remains on track to report top-line data by […]
Major updates in the biotech sector over the past four trading days were on the pipeline and regulatory front from companies like Alkermes (ALKS – Analyst Report) and Amgen (AMGN – Analyst Report) among others.Recap of the Week’s Most Important Stories1. Alkermes’ experimental schizophrenia treatment, ALKS 3831, fared well in a mid-stage study. Earlier this year, the company had said […]
Get Forex buy/sell signals directly to your email and by SMS. To learn more click hereThe silver markets went back and forth during the session on Thursday, using the $21 level as support. However, we found the $21.50 level far too resistive, so we continue to simply grind sideways overall. At the end of the day, we were essentially unchanged, […]
